RxDoctor Payments Data

John Stewart

Internal Medicine · Mt Pleasant, SCNPI 1447745831

Payments from drug & device makers

$9,553in general payments, 2019–2025

Across 520 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$996
  • Pfizer$979
  • Amgen$603
  • Novo Nordisk$603
  • Lilly USA, LLC$586
  • AstraZeneca$473
  • plus $5K from 52 others

What the payments were for

  • Speaking & faculty fees$150%
  • Food & beverage$9,527100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie71$996
Pfizer54$979
Amgen37$603
Novo Nordisk35$603
Lilly USA, LLC32$586
AstraZeneca(2 entities)21$473
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC25$430
Exact Sciences19$374
Boehringer Ingelheim18$342
Dexcom, Inc.9$330
Biohaven Pharmaceutical Holding Company Ltd.14$304
GSK16$258
Kowa Pharmaceuticals America, Inc.14$245
Amarin Pharma, Inc.12$224
Supernus Pharmaceuticals, Inc.10$203
Astellas Pharma US Inc9$195
Novartis12$177
Corium, LLC7$169
Abbott7$158
Antares Pharma, Inc.7$135
Esperion Therapeutics, Inc.8$134
Bayer8$128
Johnson & Johnson8$123
Merck6$106
Takeda Pharmaceuticals U.S.A., Inc.4$93
Sumitomo Pharma America, Inc.3$86
Daiichi Sankyo Inc.3$85
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$71
Noven Therapeutics, LLC3$69
Shield Therapeutics Inc3$65
E.r. Squibb & Sons, L.L.C.4$60
Ardelyx, Inc.2$56
Dynavax Technologies Corporation3$49
Otsuka America Pharmaceutical, Inc.2$45
Paratek Pharmaceuticals, Inc.2$45
Medicure Pharma Inc.2$45
Xeris Pharmaceuticals, Inc.2$38
Halozyme Inc2$38
Biohaven Pharmaceuticals, Inc.2$35
Renalytix AI, Inc.2$34
Sanofi-aventis U.S. LLC1$32
Phathom Pharmaceuticals, Inc.1$31
Edwards Lifesciences1$30
Phadia US Inc.1$29
Intuity Medical Inc1$26
Boston Scientific1$22
Philips North America LLC1$22
Ultragenyx Pharmaceutical Inc.1$20
Genentech USA, Inc.1$19
Avanir Pharmaceuticals, Inc.1$17
Adlon Therapeutics L.p.1$16
Sanofi Pasteur Inc.1$16
Almatica Pharma LLC1$15
Tolmar, Inc.1$15
Hikma Pharmaceuticals USA1$15
Collegium Pharmaceutical, Inc.1$15
Currax Pharmaceuticals LLC1$13
Idorsia Pharmaceuticals US Inc1$13

How this compares

$9,553 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$179,239
Medicare patients
333
Services billed
3,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$115,575
EliquisApixaban78$84,965
MounjaroTirzepatide71$76,588
JardianceEmpagliflozin75$68,784
FarxigaDapagliflozin Propanediol42$43,778
RybelsusSemaglutide24$36,192
JanuviaSitagliptin Phosphate42$30,252
TrulicityDulaglutide18$22,825
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$21,189
XareltoRivaroxaban14$21,027
EntrestoSacubitril/Valsartan18$16,571
Spiriva HandihalerTiotropium Bromide13$13,907
GemtesaVibegron18$13,489
LokelmaSodium Zirconium Cyclosilicate12$8,935
Repatha SyringeEvolocumab11$5,946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$603$151,768128 claims
Lilly USA, LLCMounjaro, Trulicity$586$99,41389 claims
PfizerEliquis$979$84,96578 claims
AstraZenecaFarxiga, Breztri Aerosphere, Lokelma$473$73,90281 claims
Boehringer IngelheimJardiance$342$68,78475 claims
MerckJanuvia$106$30,25242 claims
Johnson & JohnsonXarelto$123$21,02714 claims
NovartisEntresto$177$16,57118 claims
Sumitomo Pharma America, Inc.Gemtesa$86$13,48918 claims
AbbVieSynthroid$996$2,32433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Mt Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →